MyPeptideMatchState of Peptide Therapy in the US — 2026 Data Report
An analysis of 4,727 active peptide therapy clinics across the United States: which peptides are most widely prescribed, where clinics are concentrated, and how the GLP-1 boom has reshaped the landscape.
Key Findings
4,727
Active clinics indexed
across all 50 US states
48%
of clinics offer semaglutide
the most widely prescribed peptide
15
peptides tracked
with 100+ prescribing clinics each
FL + TX
top 2 states by clinic count
652 and 633 clinics respectively
Most Widely Prescribed Peptides by US Clinics (2026)
Ranked by number of active clinics in our database that offer each peptide. Each clinic is counted once per peptide regardless of the number of locations.
| Rank | Peptide | Clinics Offering | % of All Clinics |
|---|---|---|---|
| 1 | Semaglutide | 2,285 | 48.3% |
| 2 | Tirzepatide | 1,745 | 36.9% |
| 3 | NAD+ | 977 | 20.7% |
| 4 | Sermorelin | 777 | 16.4% |
| 5 | PT-141 | 499 | 10.6% |
| 6 | Liraglutide | 491 | 10.4% |
| 7 | BPC-157 | 308 | 6.5% |
| 8 | Tesamorelin | 258 | 5.5% |
| 9 | GHK-Cu (Copper Peptide) | 203 | 4.3% |
| 10 | Ipamorelin | 248 | 5.2% |
| 11 | CJC-1295 | 193 | 4.1% |
| 12 | TB-500 | 183 | 3.9% |
| 13 | AOD-9604 | 150 | 3.2% |
| 14 | Retatrutide | 144 | 3.0% |
| 15 | MOTS-c | 113 | 2.4% |
Data as of March 5, 2026. Source: MyPeptideMatch.com clinic database.See methodology.
The GLP-1 Boom: Semaglutide and Tirzepatide Dominate
GLP-1 receptor agonists now dominate peptide clinic offerings. Semaglutide is offered by 2,285 clinics (48% of all indexed clinics), making it by far the most common peptide in the US market — ahead of any traditional peptide therapy.
Tirzepatide ranks second at 1,745 clinics, reflecting rapid adoption following FDA approvals for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). The compounding ban effective early 2025 has shifted many clinics back to brand-name prescriptions.
Among traditional peptides (non-GLP-1), NAD+ (977 clinics) and Sermorelin (777 clinics) remain the most broadly adopted, while sexual wellness peptide PT-141 appears at 499 clinics, second only to GLP-1 compounds and NAD+ among non-growth-hormone peptides.
Clinic Density by State
Florida and Texas together account for over 27% of all active indexed peptide therapy clinics in the US. Sun Belt states dominate, likely reflecting favorable regulatory environments, telehealth adoption, and population demographics.
Methodology
Data source: MyPeptideMatch.com maintains an independent database of US clinics that offer peptide therapy, hormone optimization, medical weight loss, and related services. Data is collected through a combination of publicly available information, clinic self-submission, and third-party verification.
Inclusion criteria: Clinics marked as "active" in the database as of the data pull date (March 5, 2026). A clinic is counted as offering a peptide if that peptide is listed in their services profile.
Limitations: This database represents a significant but not exhaustive sample of US clinics. Clinics not listed in the database are not counted. Peptide offering data relies on clinic self-reporting and may not capture every service each clinic provides.
Data freshness: This report reflects a snapshot as of March 5, 2026. The underlying database is updated continuously; the figures on this page refresh daily.
How to Cite This Report
MyPeptideMatch.com. (2026, March 5). State of Peptide Therapy in the US — 2026 Data Report. Retrieved from https://www.mypeptidematch.com/research/peptide-therapy-report-2026
This report is freely available for citation under CC BY 4.0. When citing, please link to this URL. For media inquiries, contact us at mypeptidematch.com/contact.
Find a peptide clinic near you
Search our directory of 4,727+ active US clinics by peptide, state, and treatment type.